Kenneth John O’byrne

Q: What Schools Are Affiliated With Kenneth John O’byrne

Kenneth John O’byrne is affiliated with the following schools: Queensland University of Technology

Kenneth John O’byrne's AcademicInfluence.com Rankings

Medical

#1780

World Rank

#2156

Historical Rank

Oncology

#93

World Rank

#97

Historical Rank

medical Degrees

Kenneth John O’byrne

Philosophy

#5333

World Rank

#8101

Historical Rank

Logic

#2629

World Rank

#3645

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Why Is Kenneth John O’byrne Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kenneth John O’byrne's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. (2013) (3079)
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. (2013) (2786)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden (2018) (2193)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. (2005) (1521)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. (2019) (1372)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial (2009) (1366)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. (2015) (1298)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. (2016) (849)
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study (2011) (602)
Chronic immune activation and inflammation as the cause of malignancy (2001) (562)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. (2012) (533)
Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi (2018) (432)
First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers (2019) (364)
Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. (2005) (330)
Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems (2000) (309)
Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. (1997) (297)
Lipoxygenase metabolism: roles in tumor progression and survival (2007) (287)
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. (2013) (285)
Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer (2000) (282)
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. (2003) (282)
First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases (2016) (274)
Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. (2008) (266)
An Evaluation of Tumor Oxygenation and Gene Expression in Patients with Early Stage Non–Small Cell Lung Cancers (2006) (261)
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. (2017) (258)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial (2016) (252)
The role of inflammation in the pathogenesis of non-small cell lung cancer. (2010) (233)
Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature (2013) (232)
Galectin-1: a link between tumor hypoxia and tumor immune privilege. (2005) (231)
Targeting Nuclear Factor-Kappa B to Overcome Resistance to Chemotherapy (2013) (225)
Functions and Therapeutic Roles of Exosomes in Cancer (2014) (221)
Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. (2017) (213)
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (209)
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. (2011) (203)
Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer. (2000) (202)
Platinum-based chemotherapy in metastatic breast cancer: current status. (2004) (199)
The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. (2000) (193)
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance (2020) (185)
Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. (2005) (181)
LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. (2012) (180)
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. (2017) (179)
Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer. (2002) (178)
Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer (2008) (175)
Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. (2014) (168)
Nucleophosmin: from structure and function to disease development (2016) (165)
Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. (2014) (160)
Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. (1999) (160)
Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. (2012) (159)
Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. (2002) (156)
Hypoxia‐inducible factor‐1α in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways (2004) (155)
Long-term Outcomes Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer (2007) (151)
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. (2016) (150)
Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. (2014) (148)
Advances in the systemic therapy of malignant pleural mesothelioma (2008) (137)
Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small-cell lung cancer. (1997) (135)
Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. (2001) (131)
SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. (2004) (128)
Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. (2014) (124)
Lung cancer stem cells: The root of resistance. (2016) (121)
Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel (2019) (119)
Different patterns of stromal and cancer cell thymidine phosphorylase reactivity in non-small-cell lung cancer: impact on tumour neoangiogenesis and survival. (1998) (119)
The role of DNA repair pathways in cisplatin resistant lung cancer. (2014) (118)
The cancer stem-cell hypothesis: its emerging role in lung cancer biology and its relevance for future therapy. (2012) (118)
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. (2007) (117)
18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response (2006) (115)
Chemotherapeutic Compounds Targeting the DNA Double-Strand Break Repair Pathways: The Good, the Bad, and the Promising (2014) (112)
First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. (2011) (112)
Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. (2004) (111)
Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy (2009) (102)
Matrix metalloproteinases and cancer. (2001) (100)
Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. (2003) (99)
Angiogenesis is an independent prognostic factor in malignant mesothelioma (2001) (99)
Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study. (2016) (98)
Targeting the fibroblast growth factor receptor family in cancer. (2016) (96)
The emerging role of microRNAs in resistance to lung cancer treatments. (2015) (94)
Phospho-Akt Expression Is Associated with a Favorable Outcome in Non–Small Cell Lung Cancer (2005) (93)
Nivolumab (Nivo) + platinum-doublet chemotherapy (Chemo) vs chemo as first-line (1L) treatment (Tx) for advanced non-small cell lung cancer (NSCLC) with <1% tumor PD-L1 expression: Results from CheckMate 227. (2018) (93)
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study (2009) (89)
Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients (1999) (88)
Cyclooxygenase-2 expression is a novel prognostic factor in malignant mesothelioma. (2002) (88)
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. (2012) (85)
A biological staging model for operable non-small cell lung cancer (2001) (84)
The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer (2018) (82)
Herceptest: Her2 expression and gene amplification in non‐small cell lung cancer (2001) (81)
The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. (2010) (80)
Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. (2000) (79)
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. (2021) (79)
The beneficial effects of specialist thoracic surgery on the resection rate for non-small-cell lung cancer. (2004) (79)
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma. (2006) (79)
Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. (2006) (78)
A phase II study of bryostatin 1 in metastatic malignant melanoma. (1998) (78)
Ran Is a Potential Therapeutic Target for Cancer Cells with Molecular Changes Associated with Activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK Pathways (2011) (78)
The prognostic significance of circulating tumor cells in head and neck and non‐small‐cell lung cancer (2018) (77)
Drug Discovery Approaches Utilizing Three-Dimensional Cell Culture. (2016) (77)
Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. (2020) (77)
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 (2016) (76)
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma (2003) (76)
Human single-stranded DNA binding proteins are essential for maintaining genomic stability (2013) (75)
Gene Expression Analysis of Diagnostic Biopsies Predicts Pathological Response to Neoadjuvant Chemoradiotherapy of Esophageal Cancer (2009) (75)
Pembrolizumab‐Induced Encephalopathy: A Review of Neurological Toxicities with Immune Checkpoint Inhibitors (2017) (74)
Angiogenesis as a biomarker and target in cancer chemoprevention. (2001) (74)
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura (2003) (73)
Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials (2009) (72)
Inflammation and Cancer (2006) (71)
Receptor tyrosine kinases and their activation in melanoma (2011) (71)
Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma (2018) (70)
A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. (2000) (70)
Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. (2014) (70)
Analysis of acute‐phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer (2012) (70)
Understanding the tumor microenvironment for effective immunotherapy (2020) (69)
Vascular endothelial growth factor platelet counts, and prognosis in renal cancer (1999) (69)
Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568 (2018) (69)
Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer (2015) (68)
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. (2004) (68)
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1). (2006) (66)
Enrichment of circulating head and neck tumour cells using spiral microfluidic technology (2017) (65)
Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma (2013) (65)
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. (2014) (64)
Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo (2016) (63)
The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. (2004) (63)
Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer (2013) (63)
Targeting oxidative stress in cancer (2010) (63)
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer (1999) (62)
Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial (2013) (61)
A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer (2002) (61)
Thymidine Phosphorylase in Cancer; Enemy or Friend? (2016) (60)
BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. (2018) (59)
Potential role of bcl‐2 as a suppressor of tumour angiogenesis in non‐small‐cell lung cancer (1997) (59)
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. (2000) (57)
Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. (2003) (57)
Somatostatin, Its Receptors and Analogs, in Lung Cancer (2001) (56)
Ipilimumab-induced immune-related renal failure--a case report. (2012) (56)
Platelet‐derived endothelial cell growth factor (Thymidine Phosphorylase) expression in lung cancer (1997) (55)
Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial. (2019) (55)
Relationship Between EGFR Expression, EGFR Mutation Status, and the Efficacy of Chemotherapy Plus Cetuximab in FLEX Study Patients with Advanced Non–Small-Cell Lung Cancer (2014) (54)
Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study. (2012) (54)
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). (2015) (54)
Angiogenesis and non-small cell lung cancer. (2000) (53)
Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. (2003) (53)
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. (2006) (53)
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer. (2007) (53)
Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. (2020) (52)
Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer (2011) (52)
Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer (2012) (52)
Inflammation and cancer: the role of the immune response and angiogenesis. (2006) (52)
Afatinib as First‐line Treatment of Older Patients With EGFR Mutation‐Positive Non‐Small‐Cell Lung Cancer: Subgroup Analyses of the LUX‐Lung 3, LUX‐Lung 6, and LUX‐Lung 7 Trials (2018) (51)
COX-derived prostanoid pathways in gastrointestinal cancer development and progression: novel targets for prevention and intervention. (2012) (51)
Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC (2017) (51)
Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non–Small Cell Lung Cancer (2017) (51)
Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells (2017) (50)
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma (2012) (50)
Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. (2006) (50)
Epigenetics Underpinning the Regulation of the CXC (ELR+) Chemokines in Non-Small Cell Lung Cancer (2011) (49)
Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing (2009) (49)
Phase I study of the novel cyclic AMP (cAMP) analogue 8-chloro-cAMP in patients with cancer: toxicity, hormonal, and immunological effects. (1999) (49)
Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc). (2018) (49)
The Role of Chemotherapy in the Treatment of Adult Soft Tissue Sarcomas (1998) (49)
Targeting BRAF mutations in non-small cell lung cancer. (2019) (46)
Short term ex-vivo expansion of circulating head and neck tumour cells (2016) (45)
Phase III Study of Crizotinib Versus Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced Alk-Positive Non-Small Cell Lung Cancer (NSCLC) (Profile 1007) (2012) (45)
Targeting histone deacetylases for the treatment of disease (2008) (44)
High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. (2014) (44)
LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis (2019) (43)
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. (2016) (42)
Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: lessons from the experience of a high-volume center. (2012) (42)
Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer (2015) (42)
Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. (2012) (42)
Bone matters in lung cancer (2012) (41)
Scintigraphic imaging of small-cell lung cancer with [111In]pentetreotide, a radiolabelled somatostatin analogue. (1994) (41)
Chemotherapy induced reversible posterior leukoencephalopathy syndrome. (2007) (40)
Serum vascular endothelial growth factor load and interleukin-6 in cancer patients (2000) (40)
Somatostatin receptor expression in lung cancer. (1994) (40)
The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC (2011) (39)
Cyclooxygenase-2-Linked Attenuation of Hypoxia-Induced Pulmonary Hypertension and Intravascular Thrombosis (2008) (39)
[Breast cancer in the early stage]. (2012) (39)
Nivolumab plus ipilimumab in non-small-cell lung cancer. (2019) (38)
Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer (1999) (38)
Néstor-Guillermo Progeria Syndrome: a biochemical insight into Barrier-to-Autointegration Factor 1, alanine 12 threonine mutation (2014) (37)
OA08.02 DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result (2018) (37)
A computer image analysis system for microvessel density measurement in solid tumours (2004) (35)
hSSB1 (NABP2/ OBFC2B) is required for the repair of 8-oxo-guanine by the hOGG1-mediated base excision repair pathway (2015) (35)
Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities (2017) (35)
PARP inhibition induces BAX/BAK‐independent synthetic lethality of BRCA1‐deficient non‐small cell lung cancer (2011) (35)
The Role of Epigenetics in Resistance to Cisplatin Chemotherapy in Lung Cancer (2011) (35)
IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. (2013) (35)
Malignant Pleural Mesothelioma—An Update (2004) (35)
BRCA1 is an essential mediator of vinorelbine‐induced apoptosis in mesothelioma (2012) (34)
Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: a verification study. (2012) (34)
Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. (2004) (34)
Towards a biological staging model for operable non-small cell lung cancer. (2001) (33)
Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis (2019) (33)
Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. (2012) (33)
Somatostatin and the lung. (1993) (32)
RanGTPase: a candidate for Myc-mediated cancer progression. (2013) (32)
Extrapulmonary small cell gastric carcinoma. A case report and review of the literature. (1997) (32)
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression (2019) (31)
Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo (2013) (31)
Long Non Coding RNAs (lncRNAs) Are Dysregulated in Malignant Pleural Mesothelioma (MPM) (2013) (31)
Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage (2019) (31)
IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. (2011) (31)
Prognostic impact of vascular and lymphovascular invasion in early lung cancer (2014) (30)
Reduced thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer. (2002) (30)
Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. (2012) (30)
Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer. (2015) (30)
Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters (2014) (30)
Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): A phase III study (2005) (30)
Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform Lungscape Project (2012) (30)
Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. (1996) (29)
Differential Pathologic Variables and Outcomes across the Spectrum of Adenocarcinoma of the Esophagogastric Junction (2010) (29)
Activation of p38 MAP kinase by asbestos in rat mesothelial cells is mediated by oxidative stress. (2004) (29)
Phenotypic Characterization of Circulating Lung Cancer Cells for Clinically Actionable Targets (2019) (29)
Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). (2006) (28)
Focal expression of thymidine phosphorylase associates with CD31 positive lymphocytic aggregation and local neo-angiogenesis in non-small cell lung cancer. (1998) (28)
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. (2019) (27)
Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. (2004) (27)
KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. (2016) (27)
Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. (2005) (26)
Cisplatin and gemcitabine in the management of metastatic penile cancer. (2009) (26)
hSSB1 (NABP2/OBFC2B) is regulated by oxidative stress (2016) (26)
Radiolabelled somatostatin analogue scintigraphy in oncology (1996) (26)
Strategic targeting of the PI3K–NFκB axis in cisplatin-resistant NSCLC (2014) (25)
Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer (2011) (24)
The Therapeutic Potential of DNA Damage Repair Pathways and Genomic Stability in Lung Cancer (2020) (24)
Neoadjuvant immunotherapy for non-small cell lung cancer: right drugs, right patient, right time? (2021) (24)
DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results. (2018) (24)
A novel cyclic adenosine monophosphate analog induces hypercalcemia via production of 1,25-dihydroxyvitamin D in patients with solid tumors. (1997) (24)
Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. (2009) (24)
Bcl-2 is an independent prognostic factor and adds to a biological model for predicting outcome in operable non-small cell lung cancer. (2001) (23)
Epigenetic Regulation of Glucose Transporters in Non-Small Cell Lung Cancer (2011) (23)
SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer (2016) (22)
First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 ≥ 1%: Patient-Reported Outcomes From CheckMate 227 Part 1. (2021) (22)
Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. (2017) (22)
Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6) (2017) (22)
Genome Stability Pathways in Head and Neck Cancers (2013) (21)
A structural analysis of DNA binding by hSSB1 (NABP2/OBFC2B) in solution (2016) (21)
Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen (2000) (21)
Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. (2014) (21)
Angiogenesis and the immune response as targets for the prevention and treatment of colorectal cancer (review). (2003) (21)
IL-23R is Epigenetically Regulated and Modulated by Chemotherapy in Non-Small Cell Lung Cancer (2013) (21)
Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy (2021) (21)
Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy (2003) (20)
EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration (2009) (20)
Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine (2000) (19)
Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC. (2019) (19)
Imaging of medullary carcinoma of the thyroid using 111In-labelled anti-CEA monoclonal antibody fragments. (1992) (19)
Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience (2014) (19)
National Working Group Meeting on ALK diagnostics in lung cancer (2014) (19)
In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC (2016) (19)
Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response (2016) (18)
In Arrayed Ranks: Array Technology in the Study of Mesothelioma (2009) (18)
Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. (2000) (18)
The use of microvessel density in assessing human urological tumours (2001) (18)
Modulation of bryostatin 1 muscle toxicity by nifedipine: effects on muscle metabolism and oxygen supply. (1996) (17)
Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7) (2016) (17)
A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. (1998) (17)
Induction of thymidine phosphorylase as a pharmacodynamic end-point in patients with advanced carcinoma treated with 5-fluorouracil, folinic acid and interferon alpha (2000) (17)
Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial (2017) (17)
Phase II dose-finding trial of CAELYX™ (Stealth® liposomal doxorubicin HCL) in the treatment of advanced breast cancer (1997) (17)
Imaging of bronchial carcinoid tumours with indium-111 pentetreotide. (1994) (17)
Targeting histone deacetylases for the treatment of immune, endocrine & metabolic disorders. (2009) (17)
The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologies (2020) (17)
Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer. (2007) (16)
Randomized, double-blinded study of dacomitinib, an irreversible pan-human epidermal growth factor receptor (HER) inhibitor, versus erlotinib for second-line/third-line therapy of locally advanced/metastatic non-small cell lung cancer (ARCHER 1009). (2014) (16)
The MetLUNG study: A randomized, double-blind, phase III study of onartuzumab (MetMAb) plus erlotinib versus placebo plus erlotinib in patients with advanced, MET-positive non-small cell lung cancer (NSCLC). (2012) (16)
Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression (2017) (16)
Quality of life and survival in patients treated with radical chemoradiation alone for oesophageal cancer. (2008) (16)
Tumor Hypoxia Drives Genomic Instability (2021) (16)
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC) (2020) (16)
A phase II study of Caelyx, liposomal doxorubicin: lack of activity in patients with advanced gastric cancer (2001) (15)
Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer (2020) (15)
Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden (2015) (15)
An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurrent non-small cell lung cancer (NSCLC) (CheckMate 227) (2015) (15)
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. (2021) (15)
Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients (2021) (15)
LBA2_PRAfatinib (A) vs gefitinib (G) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7 (LL7) (2015) (15)
CheckMate 384: Phase IIIb/IV trial of nivolumab (nivo) 480 mg Q4W versus 240 mg Q2W after ≤ 12 months of nivo in previously treated advanced NSCLC. (2019) (15)
Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones? (2009) (14)
Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer (2020) (14)
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery (2015) (14)
Platinum-based chemotherapy in metastatic breast cancer: the Leicester (U.K.) experience. (2005) (13)
First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs). (2016) (13)
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. (2017) (13)
An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. (2011) (13)
Beyond PARP1: The Potential of Other Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer Therapeutics (2022) (13)
The establishment of an ISO compliant cancer biobank for Jordan and its neighboring countries through knowledge transfer and training. (2014) (13)
S85 British Thoracic Oncology Group Trial, BTOG2: Randomised phase III clinical trial of gemcitabine combined with cisplatin 50 mg/m2 (GC50) vs cisplatin 80 mg/m2 (GC80) vs carboplatin AUC 6 (GCb6) in advanced NSCLC (2011) (13)
Medical and surgical care of mesothelioma patients and their relatives carrying germline BAP1 mutations. (2022) (12)
Neoadjuvant Crizotinib in Advanced Inflammatory Myofibroblastic Tumour with ALK Gene Rearrangement (2015) (12)
Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX). (2006) (12)
Bone matters in lung cancer. (2012) (12)
Somatostatin and somatostatin analogues in medullary thyroid carcinoma. (1996) (12)
A metastatic neuroendocrine anaplastic small cell tumor in a patient with multiple endocrine neoplasia type 1 syndrome. Assessment of disease status and response to doxorubicin, cyclophosphamide, etoposide chemotherapy through scintigraphic imaging with 111in‐pentetreotide (1994) (12)
Reactive oxygen species and reactive nitrogen species in epigenetic modifications (2014) (12)
Randomised phase III trial of docetaxel/carboplatin vs MIC/MVP chemotherapy in advanced non-small cell lung cancer (NSCLC) - final results of a British Thoracic Oncology Group (BTOG) trial. (2004) (11)
Tumour angiogenesis: a novel therapeutic target in patients with malignant disease (2001) (11)
Stimulating immune responses to fight cancer: Basic biology and mechanisms (2015) (11)
Phase II study of liarozole in advanced non-small cell lung cancer. (1998) (11)
A role for IGF-1R-targeted therapies in small-cell lung cancer? (2011) (11)
How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma? (2016) (11)
Epigenetic Mechanisms in DNA Double Strand Break Repair: A Clinical Review (2021) (11)
DOK4/IRS‐5 expression is altered in clear cell renal cell carcinoma (2007) (11)
The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells (2020) (10)
Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells (2019) (10)
144TiPCheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) (2017) (10)
Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer. (1998) (10)
Chemotherapy for upper gastrointestinal tumours (2000) (10)
VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach. (2015) (10)
Targeted therapies in non-small cell lung cancer (2013) (10)
Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor (2010) (10)
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples (2020) (10)
A Rare Case of Omentum Invasive Prostate Cancer: Staging With PSMA PET/CT Imaging and Response to Systemic Therapy. (2017) (10)
Design, construction, and analysis of cell line arrays and tissue microarrays for gene expression analysis. (2011) (10)
Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227 (2018) (10)
COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks (2020) (10)
ARCHER: Dacomitinib (D; PF-00299804) versus erlotinib (E) for advanced (adv) non-small cell lung cancer (NSCLC)—A randomized double-blind phase III study. (2012) (10)
DNA repair pathways and their therapeutic potential in lung cancer (2014) (9)
The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas. (1998) (9)
Circulating tumor cell clusters: Insights into tumour dissemination and metastasis (2020) (9)
Development and characterisation of a panel of phosphatidylinositide 3-kinase – mammalian target of rapamycin inhibitor resistant lung cancer cell lines (2018) (9)
When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All? (2019) (9)
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) (2016) (9)
2nd ESMO Consensus Conference on Lung Cancer : non-small-cell lung cancer first-line/second and further lines in advanced disease (2014) (9)
Spatial profiling technologies and applications for brain cancers (2021) (9)
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227 (2022) (9)
Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells. (2008) (9)
hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases. (2017) (9)
A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. (1997) (8)
Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy (2021) (8)
Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study. (2018) (8)
hSSB1 associates with and promotes stability of the BLM helicase (2017) (8)
Rearranged During Transfection Fusions in Non-Small Cell Lung Cancer (2019) (8)
Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre (2013) (8)
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). (2015) (8)
Australian consensus statement for best practice ROS1 testing in advanced non-small cell lung cancer. (2019) (7)
Nivolumab (Nivo) + Ipilimumab (Ipi) vs Platinum-Doublet Chemotherapy (Chemo) as First-line (1L) Treatment (Tx) for Advanced Non-Small Cell Lung Cancer (NSCLC): Safety Analysis and Patient-Reported Outcomes (PROs) From CheckMate 227. (2018) (7)
Digital Holographic Imaging as a Method for Quantitative, Live Cell Imaging of Drug Response to Novel Targeted Cancer Therapies. (2019) (7)
Novel insight into the composition of human single-stranded DNA-binding protein 1 (hSSB1)-containing protein complexes (2016) (7)
9160 Molecular and clinical biomarkers of outcome with cetuximab: Data from the phase III FLEX study in non-small cell lung cancer (NSCLC) (2009) (7)
Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. (2016) (7)
S86 Quality of life in advanced non-small cell lung cancer, effects of cisplatin dose and carboplatin in combination with gemcitabine: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients (2011) (7)
Activity of Afatinib in Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations in Lux-Lung 3, A Phase III Trial of Afatinib or Cisplatin/Pemetrexed in EGFR Mutation-Positive Lung Cancer (2012) (7)
CA-125 criteria for response evaluation in ovarian cancer. (2005) (7)
Familiar drugs may prevent cancer (2001) (7)
O-101 XYOTAX™/carboplatin vs paclitaxel/carboplatin for the treatmentof PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The stellar 3 phase III study (2005) (7)
SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer (2020) (7)
Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model (2016) (7)
Prior or concurrent radiotherapy and nivolumab immunotherapy in non–small cell lung cancer (2019) (7)
Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer. (2018) (6)
Intramedullary spinal cord metastasis. (2001) (6)
DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma—A phase 3 randomized trial. (2021) (6)
A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series (2012) (6)
The MARS feasibility trial : Conclusions not supported by data - Authors' reply (2011) (6)
Phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine in patients with resectable IB-IIIA non small cell lung cancer. (2006) (6)
Epigenetic therapy in lung cancer and mesothelioma (2015) (6)
First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients (2022) (6)
Unilateral autoimmune inner ear disease in a patient with lung cancer treated with nivolumab (2020) (6)
Vascular endothelial growth factor expression in non-small cell lung cancer. (2003) (6)
Clinician Perspective on Molecular Profiling of Non-Small-Cell Lung Cancer. (2016) (6)
Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. (2021) (6)
Barrier-to-autointegration-factor (Banf1) modulates DNA double-strand break repair pathway choice via regulation of DNA-dependent kinase (DNA-PK) activity (2021) (6)
93PDAfatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7) (2017) (6)
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. (2016) (6)
Involving patients in treatment decisions: can we learn from clinical trials? (2001) (5)
P1.01-119 Modified Lung Immune Prognostic Index (mLIPI) as a Predictive Tool of Nivolumab Outcomes in Advanced NSCLC Patients (2019) (5)
Phase I study of the mitomycin C analogue BMS-181174. (1998) (5)
Infection and cancer (2001) (5)
Phase II study of the oxygen saturation curve left shifting agent BW12C in combination with the hypoxia activated drug mitomycin C in advanced colorectal cancer (2000) (5)
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. (1999) (5)
MARS: a sense of perspective and an inconvenient truth. (2013) (5)
143PD Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7 (2018) (5)
Computed tomography texture analysis of response to second-line nivolumab in metastatic non-small cell lung cancer (2020) (5)
Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets. (2019) (5)
Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients. (2015) (5)
NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy (2017) (5)
Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update (2022) (5)
The Impact of Rare Human Variants on Barrier-To-Auto-Integration Factor 1 (Banf1) Structure and Function (2021) (5)
Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. (2022) (4)
AIDS-related Kaposi's sarcoma in a patient with a normal CD4 count. (2008) (4)
Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC (2021) (4)
First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology. (2010) (4)
S88 Day case cisplatin delivery for advanced NSCLC patients: faster, cheaper, more desirable (2011) (4)
Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer (2021) (4)
Predictive Values for Molecular Diagnostics: Converting Unknown Unknowns to Known Unknowns (2014) (4)
The effects of lapatinib and neratinib on HER2 protein levels in breast cancer cell lines. (2012) (4)
ICORG 06-41: A phase II trial of single-agent sorafenib in the treatment of platinum-pretreated relapsed gastroesophageal adenocarcinoma (GECa). (2014) (4)
P3.01-039 Sequential Afatinib-Osimertinib Therapy in EGFR Mutation-Positive (EGFRm+) NSCLC: Analysis of Time on Treatment and OS (2017) (4)
LUX‐Lung 7: A Phase IIb, global, randomised, open‐label trial of afatinib vs gefitinib as first‐line treatment for patients (pts) with advanced non‐small cell lung cancer (NSCLC) harbouring activating EGFR mutations: 140PD (2016) (4)
EV, Microvesicles/MicroRNAs and Stem Cells in Cancer. (2018) (4)
Evolution, immune response, and cancer (2000) (4)
55 Randomized phase II clinical trial of cetuximab in combination with cisplatin (C) and vinorelbine (V) or CV alone in patients with advanced epidermal growth factor receptor (EGFR)-expressing non-small-cell lung cancer (NSCLC) (2003) (4)
1274P First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227 (2020) (4)
Nucleolar caspase-2: Protecting us from DNA damage (2017) (4)
Correction: Generation and Characterisation of Cisplatin-Resistant Non-Small Cell Lung Cancer Cell Lines Displaying a Stem-Like Signature (2020) (4)
Analysis of prognostic factors in chemo-naïve patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials. (2006) (4)
CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non‐small cell lung cancer: 24P (2016) (4)
P1.33: Afatinib Versus Chemotherapy for EGFR Mutation-Positive NSCLC Patients Aged ≥65 Years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC. (2016) (4)
The promise of improved drug delivery. (1999) (4)
Mechanisms of cisplatin resistance: DNA repair and cellular implications (2014) (3)
Epithelial-mesenchymal axis in head and neck cancer cell lines (2015) (3)
Neuropilin-1 expression in adenocarcinoma and squamous cell carcinoma of the lung is differentially regulated by hypoxia. (2006) (3)
S87 Delivered dose intensity of gemcitabine 1250 mg/m2 with cisplatin at 80 mg/m2 (GC80) and 50 mg/m2 (GC50) and carboplatin AUC 6 (GCb6) in a phase III trial of advanced non-small cell lung cancer (NSCLC): correlations with clinical outcomes (2011) (3)
A pilot phase II clinical trial of the 20S proteasome inhibitor bortezomib in patients with relapsed malignant pleural mesothelioma (2009) (3)
A lung cancer responding to hormonal therapy. (2010) (3)
O-109 Improved quality of life with the addition of SRL172 (killed mycobacterium vaccae) to standard chemotherapy in patients with advanced non-small cell lung cancer: Phase III results (2003) (3)
Markers of response to platinum-based chemotherapy in lung cancer (2013) (3)
Small cell lung cancer and other thoracic malignancies (2012) (3)
NOMINATOR: Feasibility of genomic testing of rare cancers to match cancer to treatment. (2020) (3)
Management of endocrine resistant breast cancer (2004) (3)
P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial: Track: Advanced NSCLC. (2016) (3)
Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver (2001) (3)
Examination of EXOSC4 as a new prognostic marker and a novel therapeutic avenue in lung adenocarcinoma: 17P (2016) (3)
79 The RON (MST1R)/MSP pathway is a potential therapeutic target in malignant pleural mesothelioma (2014) (3)
Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—a phase 3 randomised trial (2022) (3)
MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer (2021) (3)
A phase II study evaluating the effect of tamoxifen on DNA repair in melanoma patients treated with dacarbazine. (1997) (3)
FEASIBILITY PHASE OF THE MESOTHELIOMA AND RADICAL SURGERY (MARS) RANDOMISED CONTROLLED TRIAL COMPARING EXTRA-PLEURAL PNEUMONECTOMY (EPP) WITH NO EPP IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (2011) (3)
Trastuzumab (T) and pertuzumab (P)-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) in tyrosine kinase inhibitor (TKI)-treated breast cancer (BC) cell lines. (2014) (3)
Epidermal growth factor receptor (EGFR) mutation testing, from bench to practice: a single institute experience. (2014) (3)
OA02.05 CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial (2018) (3)
Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC: 75P (2016) (3)
Modern oncologic and operative outcomes for oesophageal cancer treated with curative intent. (2011) (3)
Effect of pattern of lymphocyte infiltration in NSCLC on outcome. (2016) (2)
12 VEGF autocrine survival signalling is mediated via neuropilin 1 receptor in NSCLC cells (2014) (2)
Quantitative CT texture assessment of tumour heterogeneity to predict those patients with non-small cell lung cancer most likely to benefit from immune checkpoint inhibitors. (2018) (2)
581 Angiogenesis, BCL-2 and platelet-derived endothelial cell growth factor (PD-ECGF) in non-small cell lung cancer (NSCLC) (1997) (2)
O-78 Microarray analysis of mesothelial cells treated with crocidolite, erionite, IL-1beta and TNF-alpha (2003) (2)
26PPembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH) (2017) (2)
Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naı¨ve Advanced Non-small Cell Lung Cancer (2008) (2)
Patient selection for cetuximab in NSCLC: A systematic review of candidate predictive biomarkers. (2010) (2)
Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer (2020) (2)
4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status (2021) (2)
122MO Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets): Intracranial and systemic outcomes from CheckMate 227 Part 1 (2021) (2)
P-424 Prediction of response to chemotherapy in malignant pleuralmesothelioma (MPM): Early positron emission tomography (PET) vs. computed tomography (CT) (2005) (2)
Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer (2021) (2)
The European Thoracic Oncology Platform Lungscape project: Clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer. (2013) (2)
Non-small cell lung cancer, early stage (2012) (2)
Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines display (2012) (2)
Do ethnic patients report longer lung cancer intervals than Anglo-Australian patients?: Findings from a prospective, observational cohort study. (2021) (2)
Impact and correlation of mutational load (ML) and specific mutations (mts) assessed by limited targeted profiling (LTP) with PD-L1 tumour expression (exp) in resected non-small cell lung carcinoma (NSCLC). (2017) (2)
Evaluation of the role of FDG-PET imaging in malignant pleural mesothelioma (MPM). (2006) (2)
The overexpression of SASH1 stimulates cell death in lung cancer cells: 16P (2016) (2)
VEGF and the epigenetic regulation of its receptors in non-small cell lung cancer (2009) (2)
Correction: Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells (2018) (2)
7 NFkB–IκBα interaction: a mechanism of resistance to cisplatin in NSCLC (2012) (2)
B2-04: Single agent versus combination therapy in advanced NSCLC patients with performance status 2: Results from a regression analysis of STELLAR 3 and 4 (2007) (2)
Overall Survival (OS) With Afatinib Versus Chemotherapy in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring Common (Del19/L858R) Epidermal Growth Factor Receptor Mutations (EGFR Mut): Results of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) (2014) (2)
32 LUX-Lung 3: Symptom and health-related quality of life results from a randomized phase III study in 1st-line advanced NSCLC patients harbouring EGFR mutations (2013) (2)
Phosphorylation and nuclear localisation of Akt is induced by hypoxia and associated with a poor prognosis in malignant pleural mesothelioma (2008) (2)
A Randomized Phase 2 Trial of Nivolumab and Stereotactic Ablative Body Radiotherapy (SABR) in Advanced Non-Small Cell Lung Cancer, Progressing After First- or Second-Line Chemotherapy (NIVORAD). (2021) (2)
Kdm 6 a and Kdm 6 b : Altered expression in malignant pleural mesothelioma (2017) (2)
69 Afatinib versus gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer (NSCLC) harbouring activating EGFR mutations: results of the global, randomised, open-label, phase IIb trial LUX-Lung 7 (2016) (2)
75P Inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC (2016) (2)
A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases. (2022) (2)
Lux-Lung 3: Afatinib Versus Cisplatin and Pemetrexed in Japanese Patients with Adenocarcinoma of the Lung Harboring an EGFR Mutation (2012) (2)
Rationale and study design of ARCHER: a randomized, double-blind, Phase III study of dacomitinib versus erlotinib for advanced non-small-cell lung cancer (2013) (2)
Targeting CDCA3 to improve chemotherapy response in triple negative breast cancer patients (2019) (2)
COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target (2021) (2)
Gene Expression Profiling of Human Adipocyte Responses to Insulin and IGF-I Signalling (2009) (2)
D7-06: Open Non-randomised Phase II Pilot Study of Neoadjuvant Cetuximab in combination with Cisplatin and Gemcitabine in patients with resectable Non-small Cell Lung Cancer (2007) (2)
Combination therapy with gefitinib (ZD1839) and rofecoxib in platinum-pretreated relapsed non-small-cell lung cancer (NSCLC). (2004) (2)
Perioperative epirubicin, oxaliplatin, and capectabine (EOX) in locally advanced resectable gastroesophageal junction and gastric adenocarcinoma. (2013) (2)
Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation‐positive non‐small cell lung cancer (NSCLC): Post‐hoc analyses of LUX‐Lung 3 (LL3) and LUX‐Lung 6 (LL6): 138PD (2016) (2)
1251PUPDATED ANALYSIS OF RESPONSE AND PATIENT-REPORTED OUTCOMES (PRO) IN TWO LARGE OPEN-LABEL, PHASE III STUDIES (LUX-LUNG 3 [LL3] AND LUX-LUNG 6 [LL6]) OF AFATINIB (A) VERSUS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH ADVANCED NSCLC HARBORING EGFR MUTATIONS (MUT). (2014) (1)
Prostacyclin synthase (PTGIS) expression and epigenetic regulation in non-small cell lung cancer (NSCLC). (2016) (1)
440O Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) (2016) (1)
Response to chemotherapy predicts longer survival in an individual patient meta-analysis of 1205 patients with mesothelioma (2009) (1)
14 – Microenvironment and Lung Cancer (2018) (1)
Medical resource utilization (MRU) and costs associated with paclitaxel poliglumex (PPX) compared to gemcitabine (Gem) or vinorelbine (Vin) in non-small cell lung cancer (NSCLC) patients (2007) (1)
1061 The neuropilins: critical survival factors for non-small cell lung cancer cells (2009) (1)
4 Vascular endothelial growth factor (VEGF) is an autocrine survival factor in non-small cell lung cancer (2012) (1)
Transformation or Progression from Adenocarcinoma to Small Cell Lung Cancer Detected by Serially Tracking Mutations in the Blood (2020) (1)
Minimizing sample failure rates for challenging clinical tumor samples. (2023) (1)
Epigenetic therapy for cisplatin resistance in non-small-cell lung cancer: the way forward? (2013) (1)
Lux-Lung 3: Symptom and Health-Related Quality of Life Results from a Randomized Phase III Study in 1st-Line Advanced NSCLC Patients Harbouring EGFR Mutations (2012) (1)
Abstract 1333: Isolation, characterization and expansion of circulating tumor cells in solid cancers (2019) (1)
P1.02-065 Elucidating the Role of PIM Kinase and Its Therapeutic Potential in NSCLC: Topic: Other Mutations in Thoracic Malignancies (2017) (1)
P76.64 Alternating Osimertinib and Gefitinib as Second-Line Treatment for EGFR-Mutated NSCLC Harbouring a T790M Resistance Mutation (OSCILLATE) (2021) (1)
1 Targeting NF-κB regulated pathways to overcome cisplatin resistance in non-small cell lung cancer (2014) (1)
Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in NSCLC (2008) (1)
OA23.05 First-Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX-Lung 7 (2017) (1)
109PDOVERALL SURVIVAL (OS) WITH AFATINIB (A) VS CHEMOTHERAPY (CT) IN PATIENTS (PTS) WITH NSCLC HARBOURING EGFR MUTATIONS (MUT): SUBGROUP ANALYSES BY RACE IN LUX-LUNG 3 (LL3) AND LUX-LUNG 6 (LL6) (2015) (1)
O-113 Clinical evaluation of gefitinib (Iressa, ZD1839) in combination with rofecoxib in cisplatin pre-treated relapsed non-small cell lung cancer (2003) (1)
52 Expression of the receptor MST1R/RON and its ligand MSP in malignant pleural mesothelioma (2011) (1)
The inter-relationship of hypoxia and phospho-Akt in the pathobiology of malignant pleural mesothelioma. (2006) (1)
Epigenetics Underpinning DNA Damage Repair (2015) (1)
Evaluating barriers to uptake of comprehensive genomic profiling (CGP) in advanced cancer patients (pts). (2020) (1)
MMP-9 and the epidermal growth factor signal pathway in non-small cell lung cancer (1999) (1)
Prognostic and therapeutic relevance of FLIP and procaspase 8 overexpression in non small cell lung (2019) (1)
MA02.02 A Novel 5-miR Signature Shows Promise as a Diagnostic Tool and as a Predictor of Cisplatin Response in NSCLC (2017) (1)
Clinical picture : intramedullary spinal cord metastasis (2001) (1)
62 The role of IL-20 in lung cancer-a new epigenetic target? (2007) (1)
IS4. Trials in Progress (2012) (1)
P3.01-74 Clinical and Radiological Predictors of Efficacy to Nivolumab in NSCLC: A Multi-Institutional, Retrospective Cohort Study. (2018) (1)
Epigenetic regulation of chemokine/chemokine receptor expression. (2013) (1)
Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland (2011) (1)
Lung cancer cells can alter the behaviour of normal bronchial epithelial cells through multiple mechanisms (2015) (1)
HER2 positive gastric and gastroesophageal adenocarcinoma; An Irish tertiary center experience (2014) (1)
Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer (2020) (1)
Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study (2019) (1)
100PAfatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment (2017) (1)
Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7) (2017) (1)
OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1 (2021) (1)
Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis. (2022) (1)
Human single-stranded DNA protein 1 (hSSB1): a prognostic factor and target for non-small cell lung cancer (NSCLC) treatment (2019) (1)
211 Excision of the primary in stage IV non-small cell lung cancer (NSCLC): A feasibility study (2014) (1)
Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR-Mutation Positive (EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A) (2014) (1)
Expression and prognostic influence of MMP-2, MMP-9 and TIMP-2 in non-small cell lung cancer (1999) (1)
CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx) (2019) (1)
The role of inner nuclear membrane proteins in tumourigenesis and as potential targets for cancer therapy (2022) (1)
Time-to-treatment failure (TTF) with first-line afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) advanced non-small-cell lung cancer (NSCLC): Randomized phase IIb LUX-lung 7 (LL7) trial (2016) (1)
P2.07-032 Outcomes of Nivolumab in Metastatic NSCLC Patients via the Access Program Across Multiple Tertiary Oncology Centres (2017) (1)
hSSB2 (NABP1) is required for the recruitment of RPA during the cellular response to DNA UV damage (2021) (1)
Antioestrogens and breast cancer (2001) (1)
Abstract 3384: Characterization of the tumor microenvironment and liquid biopsy in head and neck and non-small cell lung cancer (2020) (1)
7 Targeting neuropilin-1 in non-small cell lung cancer (2013) (1)
654MO High dimensional immuno-phenotyping of immunotherapy response in head and neck cancer (2022) (1)
Modified Lung Immune Predictive Index (mLIPI) as a predictive tool of nivolumab outcomes and immune related adverse events in advanced non-small cell lung cancer (NSCLC) patients (2019) (1)
IL-20 and its associated receptors in NSCLC (2008) (1)
66 Prostacyclin synthase (PTGIS): Expression and epigenetic regulation in lung cancer (2007) (1)
Activated cMyc/PIM kinase promotes resistance to PI3K/mTOR inhibition in NSCLC (2018) (1)
P-075 A comprehensive evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers (NSCLC) (2005) (1)
Matrix Metalloproteinase 9 and the Epidermal Growth Factor Signal Pathway in Operable Non-Small Cell Lung Cancer 1 (2000) (1)
Modelling reoxygenation effects in non-small cell lung cancer cell lines and showing epithelial-mesenchymal transition (2022) (1)
P3.02b-044 Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7: Topic: EGFR Clinical (2017) (1)
First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials (2017) (1)
PP 56 Suitability of advanced non-small cell lung cancer biopsies for prospective, multiple molecular analyses in clinical trials (2011) (1)
2: XRCC6BP1: A key player in cisplatin resistance and lung cancer stem cells (2017) (1)
H14Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) (2015) (1)
Abstract CT117: Evaluation of the effect of crizotinib (CRZ) on the QT interval in patients with ALK-positive non-small cell lung cancer (NSCLC) (2015) (1)
Archer: Dacomitinib (D; PF-00299804) Versus Erlotinib (E) for Advanced (ADV) NSCLC; A Randomized Double-Blind Phase III Study (2012) (0)
Investigating the link between hypoxia, Akt compartmentalization and cell survival in malignant pleural mesothelioma (2008) (0)
Abstract Listing (2016) (0)
P-024 EGF receptor profile in a cohort of chemotherapy naive patientswith stage 1A-111B non small cell lung cancer (2005) (0)
10 Targeting the IGF-1R signalling pathway in non-small cell lung cancer (NSCLC) (2011) (0)
22 Phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine in patients with resectable 1B-IIIA non-small-cell lung cancer: preliminary results (2007) (0)
CCL chemokines may play an important role in cisplatin resistance: Topic: proteins in lung cancer and proteomics (Conference Abstract) (2017) (0)
VEGF expression in non-small cell lung cancer: Correlation with effectors of arachidonic acid metabolism (2011) (0)
Identification and clinical impact of potentially actionable somatic oncogenic mutations in solid tumor samples (2020) (0)
83 HDAC expression levels may play a role in cisplatin resistant MPM (2013) (0)
TS01.06 High-Plex Digital Spatial Profiling of Non-Small-Cell Lung Cancer (NSCLC) (2021) (0)
65 Hypoxia, phosphoAkt cellular localization and cell survival (2007) (0)
Evaluation of early sequential 18F-FDG PET imaging as a prognostic indicator and predictor of response to platinum and pemetrexed chemotherapy in malignant pleural mesothelioma (MPM). (2016) (0)
Abstract 5572: Circulating tumor cells: The tumor trail left in the blood (2018) (0)
1154 POSTER Quantification and Localisation of Activated HER2 and EGFR Using High Content Analysis (HCA) (2011) (0)
Competing CNS or Systemic Progression Analysis for EGFR Mutation‐Positive NSCLC Patients on Afatinib in LUX‐Lung 3, 6, and 7: P06 (2018) (0)
HSSB1: An essential regulator of genomic integrity in lung cancer (2013) (0)
41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC) (2023) (0)
Transforming KRAS into a clinically relevant biomarker (Conference Abstract) (2017) (0)
O-138 Tumour necrosis factor-alpha cell signalling events in human bronchoepithelial cells (2003) (0)
2 Expression of the CXC (ELR+) receptor, CXCR2, is reactivated by epigenetic means in non-small cell lung cancer (2011) (0)
1797P Polo-like kinase-1 as a biomarker in resected non-small cell lung cancer (2021) (0)
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC) (2021) (0)
61 The VEGF signalling pathway and the chromatin environment in lung cancer (2007) (0)
P3.01-042 Lung Cancer Cells Can Stimulate Functional and Genotypic Modifications in Normal Bronchial Epithelial Cells: Topic: Functional Biology in Lung Cancer (2017) (0)
VDAC1 and prognosis in surgically resected non-small cell lung cancer. (2010) (0)
In with the old! Repurposing disulfiram to target cancer stem cells (CSCs) and the root of cisplatin resistance (2018) (0)
Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo (2016) (0)
PP121 High coexpression of both the epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) correlates with a poor patient prognosis in resected non-small cell lung cancer (NSCLC). (2009) (0)
P2.01-031 CCL Chemokines May Play an Important Role in Cisplatin Resistance (2017) (0)
SC27.03 Transforming KRAS into a Clinically Relevant Biomarker (2017) (0)
Lung Cancer Cells Can Stimulate Functional and Genotypic Modifications in Normal Bronchial Epithelial Cells (2017) (0)
EGFR mutation testing, from bench to practice: A single Irish institute experience. (2013) (0)
P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6: Track: Advanced NSCLC. (2016) (0)
Contents of Volume 5 (2002) (2004) (0)
P1.01-01 Clinical Relevance of Targeting Proteins Required for Mitotic Progression to Improve Chemotherapy Response in Non-Small Cell Lung Cancer (2019) (0)
High microvessel density is an independent poor prognostic factor in malignant mesothelioma (2000) (0)
Meeting report: 2nd meeting of the European Thoracic Oncology Platform (ETOP). (2010) (0)
97OEGFR MUTANT SUBSET ANALYSIS FROM ARCHER 1009: A RANDOMIZED DOUBLE BLIND PHASE 3 EFFICACY AND SAFETY STUDY OF DACOMITINIB VERSUS ERLOTINIB FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) (2015) (0)
The role of IL-20 in lung cancer: A new epigenetic target?: P3-063 (2007) (0)
12-Lipoxygenase is a potential therapeutic target in non-small cell lung cancer (2007) (0)
Lung cancer survival in Leicestershire: 1992–2006 (2009) (0)
Investigating The Role of Several Inner Nuclear Membrane Proteins In Triple Negative Breast Cancer (2022) (0)
1 Chronic exposure to TNF-α and IL-1β increases the invasive potential of a human bronchial epithelial cell line (2012) (0)
7: Normal bronchial epithelial cells exhibit altered cellular behaviour when exposed to lung cancer cells in a co-culture system (2017) (0)
The role of the arachidonic acid signalling pathway in NSCLC development and progression: novel targets for therapeutic intervention (2013) (0)
Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer (2021) (0)
Development and characterisation of a panel of phosphatidylinositide 3-kinase – mammalian target of rapamycin inhibitor resistant lung cancer cell lines (2018) (0)
Relationship Between EGFR Expression Level, EGFR Mutation Status and the Efficacy of Chemotherapy Plus Cetuximab in Flex Study Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
BRCA1 expression and efficacy of vinorelbine in malignant mesothelioma. (2011) (0)
3IN PROGNOSTIC FACTORS IN NON-SMALL CELL LUNG CANCER (2009) (0)
Establishing a clinical sequencing program for lung cancer in a public hospital (2019) (0)
Focal expression of platelet-derlved endothelial cell growth factor (PD-ECGF)triggers local neo-angiogenesls in non-small cell lung cancer (1997) (0)
5 MicroRNA profiling and characterisation of putative cancer stem cells in cisplatin resistant NSCLC (2014) (0)
P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC (2017) (0)
118 Delineation of spatial tissue signatures of immunotherapy response groups in non-small cell lung cancer (NSCLC) (2022) (0)
High Expression of Macrophage Stimulating Protein (MSP) Correlates with Survival Benefit in Malignant Pleural Mesothelioma (2012) (0)
7 Expression and regulation of IL-23 in NSCLC (2011) (0)
Epigenetic regulation of prostacyclin synthase (PTGIS) in non-small cell lung cancer (NSCLC) (2009) (0)
The role of the immune microenvironment in EGFR mutant NSCLC (2021) (0)
Banf1 as a marker of lung cancer cell sensitivity to cisplatin (2019) (0)
Novel role of hSSB2 in the Base Excision Repair Pathway (BER) (Conference Abstract) (2017) (0)
SP-325 elective cyclooxygenase (COX)-2 inhibitors in combination with cytokines induce growth arrest in non-small cell lung cancer cell lines at clinically relevant doses (2003) (0)
Abstract A64: NFκB-IκBα Interaction: A Mechanism of Resistance to Cisplatin in Non Small Cell Lung Cancer (NSCLC) (2012) (0)
EP receptors in NSCLC, and their regulation by epigenetic modifications (2008) (0)
56: Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma (2017) (0)
The prognostic significance of intra-tumoural vascular invasion in surgically resected non-small cell lung cancer (2010) (0)
9 Circulating tumour cells in non-small cell lung cancer, isolation and subset analysis using VitaAssay modified invasion assay (2012) (0)
Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Cell-Free DNA in Two Phase III Studies (LUX-Lung 3 and LUX-Lung 6) of Afatinib vs Platinum-Based Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer (2014) (0)
An Unusual Case of Peritoneal Metastasis From Prostate Cancer (2016) (0)
Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer (2021) (0)
Elucidating drug resistance mechanisms using 2D and 3D culture systems: 74P (2016) (0)
Epigenetic regulation of the vascular endothelial growth factor receptors: role as a cell survival factor in non-small cell lung cancer (2008) (0)
P3.03-021 When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?: Topic: Mesothelioma Transitional (2017) (0)
Examination of 12-lipoxygenase as a therapeutic target in non-small cell lung cancer (NSCLC): Mechanisms controlling survival and induction of apoptosis following selective inhibition (2010) (0)
Final Results of the Dream Trial: A Phase 2 Trial of Durvalumab with First-Line Chemotherapy in Mesothelioma with a Safety Run-In (2020) (0)
The role of the arachidonic acid pathway in NSCLC development and progression : novel approaches for therapeutic intervention (2013) (0)
85 KAT5 and KDM6B may be candidate therapeutic targets in malignant pleural mesothelioma (2013) (0)
P2-120: BH3 domain of BID induces potent and selective apoptosis of non-small cell lung cancer cells: mechanisms and implications for therapy (2007) (0)
Defining COMMD4 as an anti-cancer therapeutic target and potential diagnostic biomarker in lung cancer (2019) (0)
43 Highly multiplexed digital spatial profiling of the tumor microenvironment of non-small-cell lung cancer (NSCLC) (2020) (0)
iPREDICT: Incorporating complex profiling of patients to enrol onto molecularly directed cancer therapeutics. Preliminary results of the adult and paediatric (2019) (0)
Factors influencing disease control in metastatic lung cancer with intracranial metastasis post gamma-knife radiotherapy. (2020) (0)
P3.02c-010 Resistance Mechanisms to PI3K-mTOR Inhibition in NSCLC: Topic: Targeted Therapy (2017) (0)
Elucidating drug resistance mechanisms using 2D and 3D culture systems [Conference Abstract - ELCC 2016] (2016) (0)
Molecular mechanisms of cisplatin resistance in lung cancer (2013) (0)
951 Phase I study of batimastat (BB94) in the treatment of malignant pleural effusions (1995) (0)
2 MicroRNA profiling and cisplatin–DNA interactions in an isogenic model of cisplatin resistant NSCLC cell lines (2013) (0)
Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden (2014) (0)
RON receptor tyrosine kinase as a potential translational therapeutic target in malignant pleural mesothelioma (2010) (0)
P-489 Hypoxia inducible factor-1 alpha in non-small cell lung cancer: Relation to other biological factors and prognosis (2003) (0)
80 Epigenetic readers and writers as therapeutic targets in malignant pleural mesothelioma (2014) (0)
3 Chromosomal and mutational analysis of the cisplatin resistant phenotype in NSCLC (2014) (0)
PARP inhibition increases sensitivity of NSCLC cells to cisplatin (2013) (0)
2 IL-23A is epigenetically regulated in non small cell lung cancer (2012) (0)
Altered expression profiles of PGIS and TXS in NSCLC: regulation of tumour cell growth and invasive potential (2008) (0)
1 Elucidating the role of inflammatory mediators in cisplatin resistant NSCLC (2013) (0)
5 High content analysis (HCA) assay for the quantification and localisation of activated HER2 and EGFR (2012) (0)
8 The effects of PI3K/Akt/mTOR pathway inhibitors on a panel of NSCLC cell lines (2012) (0)
A biological prognostic model for operable non-small cell lung cancer (2000) (0)
Abstract PO-031: Aldolase A (ALDOA) is required for efficient DNA double-strand break (DSB) repair (2021) (0)
Ipilimumab in metastatic malignant melanoma: The Irish experience. (2012) (0)
82 Inhibition of RON (MST1R) induces apoptosis and decreases the cellular migration and proliferation capacity of mesothelioma cells (2013) (0)
Abstract A45: In depth molecular characterization of novel PI3K-mTOR inhibitor resistant NSCLC cell lines (2015) (0)
A phase I/II study of antibody targeted therapy with CDP671/1 in advanced non-small cell lung cancer (NSCLC) (2000) (0)
10 Development and characterization of a panel of NSCLC cell lines resistant to PI3K/mTOR inhibitor GDC-0980 (2014) (0)
Targeting NFKB in Cisplatin Resistant NSCLC (2012) (0)
Evaluation of machine learning versus Cox regression in identification of factors predicting recurrence following resection of non-small cell lung cancer. (2010) (0)
9 Co-targeting the PI3K and MEK pathways in NSCLC: an in vitro evaluation and mutation prevalence in an Irish patient cohort (2014) (0)
Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: A systematic literature review and network meta-analysis. (2023) (0)
217 A randomised, concentration-controlled, comparison of standard (5 day) vs prolonged (15 day) infusions of etoposide phosphate in small cell lung cancer (SCLC) (1997) (0)
842 FLIP as a Critical Target for Vorinostat in Mesothelioma (2012) (0)
Carbonic A nhydrase I X E xpression, a N ovel S urrogate M arker of T umor H ypoxia, I s A ssociated W ith a P oor P rognosis i n Non-Small-Cell L ung C ancer (2003) (0)
645 POSTER Effect of estrogen on outcome in two randomized phase III studies of paclitaxel poliglumex (PPX) in advanced non-small cell lung cancer (NSCLC) (2006) (0)
60 Insulin receptor substrate 5 (IRS-5). Its regulation and altered expression in cancer (2007) (0)
P-015 Hypoxic regulation of the cyclooxygenase isozymes in lungcancer mediates tumour cell survival under serum-depleted conditions (2005) (0)
Structural investigation of CDCA3‐Cdh1 protein–protein interactions using in vitro studies and molecular dynamics simulation (2023) (0)
Abstract B25: The Effects of PI3K/Akt/mTOR Pathway Inhibitors on a Panel of Non Small Cell Lung Cancer (NSCLC) Cell Lines (2012) (0)
Original article A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer (2005) (0)
Evaluating the roles of TNF, IL-1 and hypoxia in lung carcinogenesis (2009) (0)
P1.14-22 SASH1, a Novel Prognostic and Predictive Factor for PARP Inhibitors in Lung Cancer (2019) (0)
87 Expression of SDHB in malignant pleural mesothelioma (2013) (0)
The role of protein tyrosine phosphatase non-receptor 11 (PTPN11) mutations in lung squamous cell carcinoma (SQCC). (2014) (0)
841 poster INDUCTION TPF IN LOCALLY ADVANCED HEAD AND NECK CANCER IN THE COMMUNITY SETTING: OUTCOMES AND TOXICITIES (2011) (0)
117 High-plex spatial proteomic profiling of immunotherapy response groups in head and neck cancer identifies tissue signatures associated with therapy response (2022) (0)
606 Total enolase: A potential tumour marker in lung cancer (1997) (0)
Inflammatory meditated mechanisms of cisplatin resistance in non‐small cell lung cancer: 68P (2016) (0)
Inflammation in lung carcinogenesis (2013) (0)
63 Neuropilin-1 blockade inhibits hypoxia-induced Akt and MAPK phosphorylation and induces apoptosis of non-small cell lung cancer cells (2007) (0)
Anatomy of a phase III clinical trial: vivisecting BTOG2 (2008) (0)
Human single-stranded DNA protein 1 (hSSB1): a new prognostic tool and target for non-small cell lung cancer treatment (2019) (0)
Investigation of the interaction between non‐small cell lung cancer cells and immortalised normal bronchial epithelial cells: 67P (2016) (0)
Targeting aldehyde dehydrogenase 1 (ALDH1) cancer stem cell activity to circumvent cisplatin resistance in NSCLC (2017) (0)
High coexpression of both the epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor-1 (IGF-1R) correlates with a poor patient prognosis in resected non-small cell lung cancer (NSCLC) (2010) (0)
Early sequential PET scanning and use of modified RECIST criteria in the evaluation of malignant pleural mesothelioma (MPM) (2010) (0)
Implementation of precision oncology in breast cancer care in Qld (Q-IMPROvE). (2019) (0)
Neuropilin-1 regulates tumor cell survival in lung cancer cell lines under serum depleted conditions (2005) (0)
5 A novel microRNA signature associated with cisplatin resistant NSCLC holds both diagnostic and prognostic biomarker potential (2016) (0)
5 The generation and characterisation of cisplatin resistant non-small cell lung cancer cell lines that display stem-like features (2011) (0)
Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer (2020) (0)
P1.03-041 Exploitation of the Cancer Stem Cell Marker ALDH1 Within the Vitamin a/Retinoic Acid Axis Promotes Re-Sensitization of Cisplatin Resistant NSCLC (2017) (0)
97PD THE INFLUENCE OF GENDER AND SMOKING STATUS ON OVERALL SURVIVAL IN SURGICALLY RESECTED NON-SMALL CELL LUNG CANCER (2009) (0)
Effect of figitumumab (CP-751871) on the pharmacokinetics of cisplatin and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC). (2010) (0)
Investigation of thromboxane synthase expression profile as a potential survival factor in NSCLC (2009) (0)
P1.09-006 JMJ and BRD Domain Family Members in Malignant Pleural Mesothelioma: Potential Therapeutic Targets or Not? (2017) (0)
P3.01-064 The Overexpression and Cleavage of SASH1 by Caspase-3 Stimulates Cell Death in Lung Cancer Cells: Topic: Apoptosis in Lung Cancer (2017) (0)
cell lung cancer : Results from a British Thoracic Oncology Group randomised phase III trial (2017) (0)
69 Blockade of neuropilin-1 decreases NSCLC survival by regulating angiogenic and apoptotic gene expression (2007) (0)
P3.01-075 Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm+ NSCLC (2017) (0)
446PAfatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged ≥65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6) (2015) (0)
COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks (2021) (0)
Targeting CDCA3 enhances sensitivity to platinum-based chemotherapy in non-small cell lung cancer (Conference Abstract) (2017) (0)
5 IL-23R is expressed and regulated epigenetically in non small cell lung cancer (2013) (0)
MA 03.11 Targeting CDCA3 Enhances Sensitivity to Platinum-Based Chemotherapy in Non-Small Cell Lung Cancer (2017) (0)
P1.03-05 COMMD4 in Lung Cancer: Towards a New Therapeutic Target and Diagnostic Biomarker (2019) (0)
Tumour necrosis as an independent prognostic marker in non-small cell lung cancer (2001) (0)
Modern operative and oncological outcome in oesophagel cancer (2011) (0)
54: An evaluation of lysine demethylase family members in malignant pleural mesothelioma (2015) (0)
2: Platinum-induced DNA damage and repair mechanisms in non-small cell lung cancer (2015) (0)
Is miR-34a the micromanager of cancer stemness and resistance in NSCLC? (2018) (0)
P2.03a-062 Characterization and Targeting of the DNA Repair Gene, XRCC6BP1, in Cisplatin Resistant NSCLC (2017) (0)
BBI608, a small molecule stemness inhibitor, packs a big punch against cisplatin resistant NSCLC (2018) (0)
The IGF-1R pathway in NSCLC. Expression, mutational analysis and activation by hypoxia (2010) (0)
9 Elucidating the role of the NFkB pathway in cisplatin resistant NSCLC (2013) (0)
O-153 Results of a phase II trial of EGF-P64 vaccine in patients with (2003) (0)
Dihydropyridine receptor blockers and skeletal muscle metabolism. (1996) (0)
8 Exploitation of the vitamin A/retinoic acid axis in the re-sensitisation of cisplatin resistant NSCLC cells (2016) (0)
Abstract B25: PI3K targeted inhibition in NSCLC: An in vitro evaluation and correlation of mutation status to activated PI3K pathway signaling in NSCLC patients (2015) (0)
Book Review (2008) (0)
Elevating CDCA3 levels in non-small cell lung cancer enhances sensitivity to platinum-based chemotherapy (2021) (0)
91 Follow-up of patients with advanced NSCLC following 1st line chemotherapy. A British Thoracic Oncology Group national survey (2012) (0)
The effect of PARP inhibition on BAX/BAK independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. (2011) (0)
Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors. (2022) (0)
Metabolic targeting, HDAC inhibitors, and non small cell lung cancer? (2009) (0)
P2.07-033 Anti-PD1-Induced Rotator Cuff Injury: A Case Series (2017) (0)
Session 5-1 Matrix metalloproteinase disruption of the extracellular matrix and cardiovascular disease (2009) (0)
6 The expression and role of thromboxane synthase in NSCLC: correlation with angiogenic factors and patient survival (2011) (0)
5: Mechanisms of resistance to dual PI3K–mTOR inhibition in NSCLC cell lines (2015) (0)
Identifying driver mutations in squamous cell lung cancer (SCC): The Lung Cancer Genomics Ireland (LCGI) study. (2015) (0)
Meeting the Challenge of Oral Anti-Cancer Therapy Education – An Irish Perspective (2012) (0)
63 Chemotherapy for malignant mesothelioma and response assessment by modified RECIST criteria, the St James's Hospital, Dublin experience (2012) (0)
Quantification of cisplatin uptake by lung cancer cells using ICP-MS. (2013) (0)
216P COMMD1 in non-small cell lung cancer: A novel DNA repair protein as a therapeutic target and diagnostic biomarker (2021) (0)
Nuclear Factor-Kappa B as a Molecular Target in Malignant Pleural Mesothelioma (2012) (0)
P2.03a-063 Small Molecule Cancer Stemness Inhibitor, BBI608, Restores Cisplatin Sensitivity in Resistant NSCLC: Topic: Clinical Trials (2017) (0)
MicroRNA profiling and cisplatin-DNA interactions in an isogenic model of cisplatin resistant NSCLC cell lines [Conference Abstract] (2013) (0)
1013P Utilizing a combined biomarker and therapeutic strategy to reverse TKI resistance in EGFR mutant non-small cell lung cancer (2022) (0)
Systemic and intracranial outcomes with first-line nivolumab plus ipilimumab in patients with metastatic non-small cell lung cancer and baseline brain metastases from CheckMate 227 Part 1. (2023) (0)
1153P A first in class DNA repair inhibitor for the treatment of NSCLC (2022) (0)
Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) withEGFRmutation-positive (EGFRm+) NSCLC: LUX-Lung 7 (2016) (0)
Chloropyramine increases NSCLC sensitivity to cisplatin in a SASH1 dependent manner (2019) (0)
Neuropilin-1 blockade inhibits hypoxia-induced Akt and MAPK phosphorylation and induces apoptosis of non-small cell lung cancer cells: PD2-1-6 (2007) (0)
P1.03-048 miR-34a and the Micromanagement of Cancer Stemness and Resistance in NSCLC. Does It Hold Therapeutic Benefit? (2017) (0)
Progression of Well-Differentiated Papillary Mesothelial Tumour to Mesothelioma in a Patient with Ehlers Danlos Syndrome (2021) (0)
P2.14-60 Afatinib in EGFR Mutation-Positive NSCLC: Activity in Patients with Brain Metastases, and Impact on CNS Progression/Spread (2019) (0)
Novel treatments for mesothelioma (2006) (0)
P59.16 Characterizing the Tumour-Immune Microenvironment in EGFR Mutant NSCLC (2021) (0)
Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer (2015) (0)
PP 15 BRCA1 expression is required for efficacy of vinorelbine and is a predictive biomarker in malignant mesothelioma (2011) (0)
PP111 Examination of the expression profiles of PGIS and TXS in NSCLC: Regulation of tumor cell growth and invasive potential (2009) (0)
5IN ESMO NON-SMALL-CELL LUNG CANCER (NSCLC) CONSENSUS ON PATHOLOGY AND MOLECULAR TESTING (2011) (0)
P1.09-07 The Clinical Utility and Performance of Whole-Exome Sequencing for NSCLC Patient Care: A Comparison to Standard-of-Care (2019) (0)
Bcl-2, angiogenesis, necrosis and macrophages in early breast cancer (2000) (0)
6 Circulating tumour cells in NSCLC. Enumeration and analysis using VitaAssay and Screencell techniques (2013) (0)
Vascular endothelial growth factor expression in lung cancer. (1998) (0)
Circulating tumour cells in head and neck and non-small cell lung cancer (2019) (0)
P2.03b-096 Utilization of a Novel 3D Culture Technology for the Assessment of Chemo-Resistance in Non-Small Cell Lung Cancer: Topic: Biomarkers (2017) (0)
‘Invading edge vs. inner’ vascularisation: angio-genic and angio-preserving activity in non-small cell lung cancer (NSCLC) (1999) (0)
Multi-omic and spatial dissection of immunotherapy response groups in non-small cell lung cancer. (2022) (0)
Systemic Treatment for Advanced NSCLC (2014) (0)
Identification of a novel microRNA signature: Potential diagnostic biomarkers and predictors of cisplatin response?: 70P (2016) (0)
Big applications for a microRNA signature: the diagnostic, prognostic and predictive biomarker potential of a novel 5-miR signature associated with cisplatin resistant NSCLC (2018) (0)
86 When RON MET TAM: potential interventions for mesothelioma therapy (2016) (0)
22 Costs of cisplatin and carboplatin in combination with gemcitabine in advanced non-small cell lung cancer: results from BTOG2, a British Thoracic Oncology Group phase III trial in 1363 patients (2012) (0)
Phase II study of sabarubicin (MEN 10755) in newly diagnosed patients with extensive stage small cell lung cancer (ESCLC): Final report (2008) (0)
Durable complete response to immunotherapy in treatment‐resistant metastatic colorectal cancer with thyroid transcription factor 1 expression (2020) (0)
P1.02-010 Novel Role of hSSB2 in the Base Excision Repair Pathway (BER) (2017) (0)
54LBA High coexpression of both the insulin-like growth factor receptor-1 (IGF-1R) and epidermal growth factor receptor (EGFR) correlates with a poor patient prognosis in resected non-small cell lung cancer (NSCLC) (2009) (0)
Genetic mutations and signatures in lung cancer – findings from a whole exome sequencing platform (2021) (0)
Abstract A03: Isolation, characterization, and expansion of circulating tumor cells in head and neck cancers (2020) (0)
P2-050: Blockade of neuropilin-1 decreases NSCLC survival by regulating angiogenic and apoptotic gene expression (2007) (0)
Targeting Inflammatory Mediators to Overcome Intrinsic and Acquired Cisplatin Resistance in Non-Small Cell Lung Cancer (2015) (0)
P1.09-007 Targeting MET/TAM Receptors in Mesothelioma: Are Multi-TKIs Superior to Specific TKI? (2017) (0)
P1.03-19 Circulating Tumour Cells in Non-Small Cell Lung Cancer (2019) (0)
1302P Immune signatures of second-line PD-1 immune checkpoint blockade (2021) (0)
MST1R, a receptor tyrosine kinase expressed in malignant pleural mesothelioma. (2010) (0)
64 Macrophage stimulating protein (MSP) up-regulates the Src kinases in malignant pleural mesothelioma (2012) (0)
16P Stromal compartment specific gene signatures dissect immunotherapy response groups in non-small cell lung cancer (2021) (0)
Culture of circulating tumour cells derived from non-small cell lung cancer. (2020) (0)
XRCC6BP1: A key DNA repair gene in platinum‐resistant NSCLC: 80P (2016) (0)
1243PDACOMITINIB (D) VERSUS ERLOTINIB (E) IN 2ND/3RD LINE NSCLC: OUTCOME FOR ASIAN PATIENTS FROM THE ARCHER 1009 GLOBAL PHASE 3 TRIAL. (2014) (0)
P2.02-048 Survival Correlation Between TP53 Gene and PD-L1 Tumor Expression in Resected Non-Small Cell Lung Carcinoma (2017) (0)
CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non-small cell lung cancer [Conference Abstract - ELCC 2016] (2016) (0)
4 Inhibition of PARP activity by PJ34 sensitises NSCLC cells to cisplatin (2014) (0)
RanGTPase is transcriptionally regulated by Myc and is required for Myc-mediated cancer progression (2012) (0)
3 The establishment of an isogenic model of cisplatin resistance and the identification of a potential microRNA signature in non-small cell lung cancer (2012) (0)
FP07.05 DREAM3R: Durvalumab With Chemotherapy as First Line Treatment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial (2021) (0)
CheckMate 227: Nivolumab + Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden: PS2 (2018) (0)
encephalopathy Following Treatment With Pembrolizumab For Metastatic Non–small Cell Lung Cancer: A Case Report (2016) (0)
6 Cisplatin induces the emergence and expansion of a distinct cancer stem cell (CSC) population in NSCLC (2016) (0)
Protein tyrosine phosphatase non receptor 11 (PTPN11/Shp2) as a driver oncogene and a novel therapeutic target in non-small cell lung cancer (NSCLC). (2015) (0)
68 Mechanisms controlling survival and induction of apoptosis following 12-lipoxygenase (LOX) inhibition in non small cell lung cancer (NSCLC) (2007) (0)
P24.10 Identification of ctDNA using MassARRAY Technology in a Cross-Sectional Study of NSCLC Patients (2021) (0)
Examination of 12-lipoxygenase (12-LOX) as a therapeutic target in non-small cell lung cancer (NSCLC): Mechanisms controlling survival and induction of apoptosis following selective inhibition. (2011) (0)
4 VEGF is an autocrine survival factor in non-small cell lung cancer (2011) (0)
1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02) (2021) (0)
P2.01-081 CDCA3 is a novel prognostic cell cycle protein and target for therapy in non-small cell lung cancer (2017) (0)
Enhancing sensitivity to platinum-based therapy by suppressing the novel prognostic factor CDCA3 in non- small cell lung cancer (2019) (0)
IL-23 is Epigenetically Regulated and Induced by Chemotherapy in NSCLC (2012) (0)
4 Identification and targeting of the DNA repair gene, XRCC6BP1, in cisplatin resistant NSCLC (2016) (0)
Lymph nodes dissection, implication on prognosis in surgical non-small cell lung cancer (2010) (0)
EP16.04-003 High Dimensional Spatial Profiling of the NSCLC Tumour Microenvironment (2022) (0)
Activation of the macrophage-stimulating protein (MSP)-RON axis in malignant pleural mesothelioma. (2011) (0)
P2.03a-064 Inhibition and Exploitation of Aldehyde Dehydrogenase 1 as a Cancer Stem Cell Marker to Overcome Cisplatin Resistant NSCLC: Topic: Clinical Trials (2017) (0)
CT texture analysis as a predictor of effectiveness of second line nivolumab in metastatic non-small cell lung cancer (2019) (0)
Activation of Akt by Hypoxia Predicts Poor Outcome in Malignant Pleural Mesothelioma (MPM) (2012) (0)
4 DHMEQ, an NFkB inhibitor, inhibits cell proliferation and induces apoptosis in cisplatin resistant NSCLC (2013) (0)
A carrot a day keeps recurrence away! The use of vitamin A and its metabolic products in the circumvention of cisplatin resistance via Aldehyde Dehydrogenase 1 (ALDH1) (2018) (0)
7 Cancer stem cells: targeting aldehyde dehydrogenase 1 (ALDH1) as a novel strategy to overcome cisplatin resistance in NSCLC (2016) (0)
67 Can HDAC expression be used to stratify mesothelioma patients for appropriate treatment regimens (2012) (0)
4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer (2015) (0)
Matrix metalloproteinase expression in normal, inflammed and malignant mesothelial tissues (1999) (0)
hSSB1 (NABP2/OBFC2B) modulates the DNA damage and androgen‐induced transcriptional response in prostate cancer (2023) (0)
P-106 Neuropilin-1 regulates tumour cell survival in lung cancer celllines under serum depleted conditions (2005) (0)
Investigation of the interaction between non-small cell lung cancer cells and immortalised normal bronchial epithelial cells (2016) (0)
A role for IGF-1R targeted therapy in SCLC? (2010) (0)
P1.03-042 BBI608, a Small Molecule Stemness Inhibitor, Circumvents Cisplatin Resistance in NSCLC (2017) (0)
P2.02-069 Targeting Neuropilin-1 in NSCLC (2017) (0)
Activation of NF-κB by Asbestos through EGF-R Signalling in Mesothelial Cells is Important in Cell Survival (2002) (0)
PP120 Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis in resected non-small cell lung cancer (2009) (0)
Normal bronchial epithelial cells exhibit altered cellular behaviour when exposed to lung cancer cells in a co-culture system (Conference Abstract) (2017) (0)
P2.02-064 A Novel 5-miR Signature Shows Potential as a Diagnostic Tool and as a Predictive Biomarker of Cisplatin Response in NSCLC (2017) (0)
Expression and prognostic significance of tissue hypoxia markers in head and neck squamous cell carcinomas (HNSCC) (2005) (0)
86 Evaluating BMS-777607 as a candidate therapeutic agent in malignant pleural mesothelioma (2013) (0)
P1.03-039 Therapeutic Inhibition of the Cancer Stem Cell Marker, ALDH1, a Promising Mechanism by Which Cisplatin Sensitivity Can Be Restored in NSCLC (2017) (0)
Microrna Profiling and CDDP-GPG DNA Adduct Formation Analysis in a Panel of Cisplatin Resistant Non-Small Cell Lung Cancer Cell Lines (2012) (0)
Phase I study of liposomal daunorubicin (Daunoxome) in the treatment of metastatic breast cancer (1999) (0)
Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer (2022) (0)
PD-097 Macrophage and mast cell invasion of tumour cell islets confers a marked survival benefit in non-small-cell lung cancer (2005) (0)
P2-069: A Retrospective Clinicopathological Study of the Epidermal Growth Factor Receptor (EGFR) profile in patients with resectable non small cell lung cancer (2007) (0)
Abstract 702: RON receptor tyrosine kinase: A potential therapeutic target in malignant pleural mesothelioma (2010) (0)
P2.14-08 Banf1 Predicts Lung Cancer Survival and Sensitivity to Platinum-Based Chemotherapy (2019) (0)
O-104DOES THE TIMING OF CHEMOTHERAPY AFFECT OUTCOME FOLLOWING RADICAL SURGERY FOR MALIGNANT PLEURAL MESOTHELIOMA? (2014) (0)
2 p53 gene status and modulation of response to cisplatin chemotherapy in non-small cell lung cancer cells (2014) (0)
Co-Targeting The PI3K-MTOR & MEK Pathways in NSCLC (2012) (0)
P-479 The expression and prognostic significance of Akt and phosphorylated Akt (pAkt) in non-small cell lung cancer (2003) (0)
A Phase II Study of Razoxane , an Antiangiogenic Topoisomerase II Inhibitor , in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis 1 (2000) (0)
CDCA3 is a novel prognostic cell cycle protein and target for therapy in non-small cell lung cancer: Topic: Marker for prognosis (Conference Abstract) (2017) (0)
Array Technology in the Study of Mesothelioma (2009) (0)
Utilization of a novel 3D culture technology for the assessment of chemo-resistance in non-small cell lung cancer: Topic: biomarkers (Conference Abstract) (2017) (0)
P2-039: Mechanisms controlling survival and induction of apoptosis following 12-lipoxygenase (LOX) inhibition in non small cell lung cancer (NSCLC) (2007) (0)
8 PIK3CA mutations and response to PI3K and MEK targeted therapies in NSCLC (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kenneth John O’byrne?

Kenneth John O’byrne is affiliated with the following schools:

Queensland University of Technology

Kenneth John O’byrne's Academic­Influence.com Rankings

Why Is Kenneth John O’byrne Influential?

Kenneth John O’byrne's Published Works

Published Works

What Schools Are Affiliated With Kenneth John O’byrne?

Kenneth John O’byrne's AcademicInfluence.com Rankings